CAS: 90902-21-9

Broussonin E could suppress inflammation by modulating macrophages activation state via inhibiting the ERK and p38 MAPK and enhancing JAK2-STAT3 signaling pathway, and can be further developed as a promising drug for the treatment of inflammation-related

Broussonin E is a natural compound that belongs to the group of flavonoids, which is derived from plant sources, particularly from the Broussonetia genus. This small molecule acts primarily through the inhibition of pro-inflammatory pathways, particularly cyclooxygenase (COX) enzymes. As an inhibitor, it impedes the conversion of arachidonic acid to prostaglandins, which play a critical role in inflammation and pain signaling. Studies have demonstrated that Broussonin E may possess significant anti-inflammatory activities, making it a potential candidate for further research in pharmacological applications targeting inflammatory disorders. Its actions are not limited to anti-inflammatory effects; researchers are investigating Broussonin E for additional biological activities, including anti-oxidative and anticancer properties. This compound presents a valuable opportunity for the identification and development of new therapeutic agents derived from natural origins, offering an alternative approach to managing chronic inflammatory conditions and potentially other diseases influenced by oxidative stress.